Related Experiment Video
Updated: Apr 5, 2026
Accessing the Cytotoxicity and Cell Response to Biomaterials
Published on: July 8, 2021
Andrographolide Exerts Pro-Osteogenic Effect by Activation of Wnt/β-Catenin Signaling Pathway in Vitro
Tongmeng Jiang1, Bo Zhou, Li Huang
1Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, China.
Background/Aims:
Osteoporosis is a metabolic bone disorders that tortures about millions of people worldwide. Recent studies showed that Andrographolide (AP) is a promising natural compound for the treatment of osteoclast-related bone diseases. However, its potential in treatment of osteoporosis has not been fully explored.
Methods:
In this study, the effect of AP on osteoblasts metabolism was investigated via the detection of cell proliferation, cell viability, ALP activity, the expression of osteogenic specific genes including runt-related transcription factor 2 (RUNX2), bone sialoprotein (BSP), osteocalcin (OCN), Bone morphogenic protein-2 (BMP2) and Alkaline phosphatase(ALP) for 3, 5 and 7 days respectively. Further exploration of the association of AP with WNT/β-catenin signaling pathway was performed by examination of the expression of WNT related genes and proteins.
Results:
Results showed that AP of 4.46 and 8.92 µM, especially 8.92 µM was beneficial to osteogenic differentiation by upregulating ALP activity and expression of osteogenic related genes (P<0.05). Pathway analyses identify canonical WNT/β-catenin pathway as an important mediator in AP-induced osteogenesis.
Conclusion:
This study indicates that AP exerts its pro-osteogenic potential via activation of the WNT/β-catenin in osteoblasts and thus may represent a candidate of therapeutic agent for osteoporosis.
Insights
Andrographolide (AP) promotes osteogenic differentiation in osteoblasts by activating the WNT/β-catenin pathway. This natural compound shows potential as a therapeutic agent for osteoporosis treatment.
Area of Science:
- Bone Biology and Metabolism
- Pharmacology
- Natural Product Therapeutics
Background:
- Osteoporosis affects millions globally, characterized by metabolic bone disorders.
- Andrographolide (AP) shows promise for osteoclast-related bone diseases.
- AP's potential in osteoporosis treatment requires further investigation.
Purpose of the Study:
- To investigate the effect of Andrographolide (AP) on osteoblast metabolism.
- To explore the role of AP in osteogenic differentiation.
- To elucidate the association between AP and the WNT/β-catenin signaling pathway.
Main Methods:
- Assessed osteoblast proliferation, viability, and Alkaline Phosphatase (ALP) activity.
- Measured expression of key osteogenic genes (RUNX2, BSP, OCN, BMP2) over 7 days.
- Examined WNT/β-catenin pathway activation through gene and protein expression analysis.
Main Results:
- AP (especially 8.92 µM) significantly enhanced osteogenic differentiation.
- Upregulation of ALP activity and osteogenic gene expression was observed (P<0.05).
- WNT/β-catenin signaling was identified as a key mediator of AP-induced osteogenesis.
Conclusions:
- Andrographolide (AP) demonstrates pro-osteogenic potential in osteoblasts.
- AP exerts its effects through the activation of the WNT/β-catenin pathway.
- AP represents a potential therapeutic candidate for managing osteoporosis.
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
01:41Non-Canonical Wnt Signaling Pathways
01:23Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...